London, UK (PRWEB) February 24, 2014
In 2012, the combined value of the cystic fibrosis (CF) therapeutics markets in the top 8 developed economies stood at around USD 696.5 million. It is predicted to grow considerably in the years ahead, registering a 30.4% CAGR, and is forecast to amount to almost USD 4.5 billion in 2019. The market’s primary growth stimulator is the introduction of new treatment options with disease-modifying mechanisms of action. The favourable impact of novel market entrants is expected to offset the negative effects of key patent losses in the next 5 years.
The major CF treatment option are cystic fibrosis transmembrane regulators (CFTR) modulators, which tackle the very root cause of the disease rather than its symptoms, alongside offering improved relief and quality of life to patients. Kalydeco (ivacaftor) (marketed since 2012) was the first modulator launched in the CF therapeutics market, and it made a considerable contribution to the market value. This effect will likely be achieved on a greater scale when Ataluren (PTC124) and lumacaftor enter the market, as these treatment options can be applied on a much larger proportion of the CF population. The developer of lumacaftor, Kalydeco and other early-phase CFTR modulators, Vertex Pharmaceuticals Inc., is expected to play a key role in shaping the future development of the CF therapeutic market.
New research report “Cystic Fibrosis Therapeutics in Major Developed Markets to 2019 - CFTR Modulators Initiate Drive towards Personalized Treatment and Market Growth” worked out by GBI Research is now available at MarketPublishers.com.
Title: Cystic Fibrosis Therapeutics in Major Developed Markets to 2019 - CFTR Modulators Initiate Drive towards Personalized Treatment and Market Growth
Published: February, 2014
Price: US$ 3,500.00
The new report provides valuable insights into the CF therapeutics market scenario and offers an in-depth market assessment. It scrutinizes the main market barriers and drivers, covers the major market areas, and contains information (historical, actual and forecast) on the market performance. The study encloses a comprehensive product profile, including details on the disease’s symptoms, diagnostics and treatment; presents and extensive summary of the products currently marketed, identifies the unmet needs, compares the safety and efficacy of the top brands. The report includes a detailed CF pipeline analysis encompassing a review of the most important issues, such as drug distribution, CF clinical trial landscape, the most promising pipeline drugs, among others. In addition, the research report outlines the market future growth prospects, offers a complete set of the projected values as well as pinpoints the potential entry of novel products.
Reasons to Buy:
More new research reports by the publisher can be found at GBI Research page.